C12018: Novel Human PDPK1, AKT1, and AKT2 Knock-out Cell Lines for Studying CancerNovelty:
Development of modified human cancer cell lines with inactivated PDPK1 gene for studying colon cancer.
Value Proposition:
Modified human cell lines serve as useful research tools for studying the pathophysiology and cellular level differences between normal cells and cancer affected cells. This invention comprises the development of modified human cancer cell lines, HCT116 and DLD1, with inactivated PDPK1 gene. The advantages of these modified cell lines are:
• Facilitates the study of colon cancer and of other metastatic tumors under the influence of various cellular microenvironments
• Aids in ascertaining the role of the PI3K pathway in cancer prognosis
• Enables the identification of ideal drug targets for treatment of metastatic cancer
Technical Details:
Johns Hopkins researchers have created cell lines having one or both of the ATK genes inactivated, as well as a PSPK1 knock-out line. Human colon cancer cell lines HCT116 and DLD1 constitutively activated PI3K pathway due to genetic mutations of H10470R and E545K, respectively. The inactivation of both ATK genes and the PDPK1 gene resulted in a decrease in growth of metastatic tumors, indicating the role of microenvironment in determining the effects of gene disruption.
Looking for Partners:
To develop and commercialize the technology as research and life sciences study tool for studying the role cellular microenvironment in tumor growth.
Stage of Development:
Prototype
Data Availability:
Human cell studies
Publications/Associated Cases:
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2598-603
